Class dossier · CHOLINESTERASE · Draft
Soviet/Russian Cholinesterase Pharmacology — from Foliant to Exelon
Acetylcholinesterase is the most targetable enzyme in pharmacology. The same active-site gorge can be hit with four different intents, and the Soviet pharmacology institutes developed all four of them in parallel from the 1950s onward. Hit it irreversibly, and you have a nerve agent — tabun, sarin, soman, VX, the A-series. Hit it with an oxime, and you have the antidote — pralidoxime, obidoxime, dipyroxime, HI-6, the Russian carb-oxime. Hit it with a reversible carbamate, and you have a prophylactic — pyridostigmine, aminostigmine, physostigmine, galantamine. Hit it with a reversible inhibitor that crosses the blood-brain barrier, and you have an Alzheimer's drug — tacrine, donepezil, rivastigmine, galantamine again. The same Russian institutes that developed the weapons developed the antidotes and the prophylactics, often in the same building: ВНИХФИ in Moscow isolated galantamine from Caucasian snowdrop in 1951 (Mashkovsky and Kruglikova-Lvova); the Institute of Toxicology in St. Petersburg produced the carb-oxime and aminostigmine line for the FOV-antidote programme in the 1990s; GosNIIOKhT in Vol'sk developed the A-series nerve agents, until Mirzayanov walked out and told the world in 1992. Galantamine — a Soviet 1951 discovery — eventually became a Western Alzheimer's drug (Razadyne, FDA 2001). Rivastigmine, a physostigmine-scaffold carbamate developed at Hebrew University, took the same tactic to the same target and reached FDA approval in 2000. The bridge this dossier draws is: same molecule, four uses, Soviet-to-Western translation under one continuous chemistry.
1 · Definition
- Definition
- Soviet / Russian cholinesterase pharmacology — compounds designed to interact with the acetylcholinesterase (AChE) / butyrylcholinesterase (BuChE) active site. Includes four functional sub-classes: (1) IRREVERSIBLE AChE INHIBITORS as chemical weapons (G/V/A-series nerve agents); (2) OXIME AChE REACTIVATORS as antidotes (pralidoxime, obidoxime, dipyroxime/TMB-4, isonitrosine, HI-6, carb-oxime); (3) CARBAMATE REVERSIBLE AChE INHIBITORS as prophylactics OR Alzheimer therapeutics (physostigmine, pyridostigmine, aminostigmine, galantamine, rivastigmine, tacrine, donepezil, huperzine A); (4) MUSCARINIC ANTAGONISTS as adjuncts (atropine, pentiphine). The connecting thesis: the same AChE active-site chemistry runs from chemical-warfare defence to dementia therapeutics. Soviet pharmacology worked multiple sides simultaneously.
- Criteria
- Direct interaction with the AChE / BuChE active site (irreversible, reversible, or allosteric); Documented in primary Russian-language literature (CyberLeninka, disserCat, Фармакология и токсикология 1945-) or primary Soviet pharmacology textbooks (Krylov/Livanov/Petrov 1999); Connection to one or more of the four functional sub-classes above (weapon / antidote / prophylactic / therapeutic); Sourceable to a Russian institutional origin OR a Soviet-bloc discovery attribution
- Origin note
- The category is target-based (AChE / BuChE active site), not scaffold-based. Three institutional threads run through it: ВНИХФИ Moscow (galantamine isolation + early adamantane work, Mashkovsky + Kruglikova-Lvova 1951), Institute of Toxicology St. Petersburg (carb-oxime + aminostigmine + pentiphine line, Sofronov + Petrov + Nechiporenko), and GosNIIOKhT Vol'sk-18 (Foliant / A-series, Mirzayanov + Fedorov 1992 disclosure).
2 · Provenance
- Institution
- Multiple — three institutional threads
- Organizations
- ВНИХФИ (All-Union Chemical-Pharmaceutical Institute, Moscow) — Mashkovsky MD + Kruglikova-Lvova RP — galantamine isolation + anticholinesterase pharmacology 1951-1955 · GosNIIOKhT (State Research Institute of Organic Chemistry and Technology, Vol'sk-18 / Shikhany, Saratov Oblast) — Mirzayanov VS / Fedorov L — Foliant / A-series nerve-agent programme 1971-1993; Mirzayanov's 1992 disclosure in Moscow News broke the story · Institute of Toxicology of the Ministry of Health (Институт токсикологии Минздрава, St. Petersburg) — Petrov AN / Sofronov GA / Nechiporenko SP / Prozorovskii VB — oxime + carbamate + M1-blocker antidote pharmacology; principal Russian antidote-development site post-1991 · НИИ-2 МО РФ (Scientific-Research Institute-2 / Research Institute of Military Medicine, MoD RF) — pre-clinical carboxime testing · Sechenov Moscow Medical Academy (ММА им. Сеченова) — civilian clinical trials on Russian antidotes · Pharmachim (Sofia, Bulgaria) — Dimitar Paskov's Nivalin production 1958- · Aposhian lab (Univ. of Arizona) — DMPS clinical development 1980s-1990s (the Western clinical development of Soviet Unithiol)
- Key people
- Mashkovsky MD (Машковский М.Д., 1908-2002) — ВНИХФИ Moscow, canonical Soviet pharmacopoeia author; galantamine isolation + AChE pharmacology 1951 + 1955; Kruglikova-Lvova RP (Кругликова-Львова Р.П.) — ВНИХФИ Moscow, co-discoverer of galantamine AChE activity 1951; Paskov D (Димитър Пасков) — Bulgaria 1956-1959, developed galantamine as drug Nivalin (Pharmachim, Sofia 1958); Mirzayanov VS (Мирзаянов В.С.) — GosNIIOKhT, A-series/Foliant defector-whistleblower; 1992 Moscow News disclosure; 2008 memoir State Secrets; Fedorov L (Фёдоров Л.) — Union for Chemical Safety, co-author of the 1992 disclosure; Uglev V (Углев В.) — self-identified A-232/Novichok-5 co-author (2018 disclosures); Petrov AN (Петров А.Н.) — Institute of Toxicology, lead author 2004 Ros. khim. zh. FOV-antidote review (the canonical Russian open review); Sofronov GA (Софронов Г.А.) — Institute of Toxicology, aminostigmine + pentiphine line; Nechiporenko SP (Нечипоренко С.П.) — FMBA, FOV therapy review co-author; Prozorovskii VB (Прозоровский В.Б.) — Institute of Toxicology, carb-oxime prophylaxis paper (2008); Schrader G (IG Farben) — inventor of tabun (1936) and sarin (1938), founding fathers of organophosphate AChE inhibitors; Kuhn R (Kaiser Wilhelm Institute) — soman (1944); Ghosh R (ICI, Porton Down 1952) — VX; Summers WK (Loma Linda VA, 1981) — tacrine / first AChE inhibitor for Alzheimer's (FDA 1993, withdrawn 2013); Weinstock-Rosin M (Hebrew Univ. Jerusalem) — rivastigmine / Exelon (FDA 2000)
- Intellectual lineage
- Calabar bean ordeal poison (Efik people, Nigeria, ~17th c.) → Christison 1855 self-experiment → Fraser 1862 eserine → Jobst & Hesse 1864 physostigmine → Loewi 1926 (uses physostigmine to protect acetylcholine from esterase, isolates acetylcholine, 1936 Nobel with Dale) → Schrader 1936 tabun → Schrader 1938 sarin → Kuhn 1944 soman → Ghosh 1952 VX. PARALLEL: Caucasian snowdrop (Galanthus woronowii) folk medicine → Mashkovsky & Kruglikova-Lvova 1951 (first AChE pharmacology, Фармакология и токсикология 14:27-30) → Mashkovsky 1955 → Paskov Bulgaria 1956-1959 → Pharmachim Nivalin 1958 → Bandman & Anriiyanov 1982 → Heinrich & Lee 2004 J Ethnopharmacol review → Sanochemia (Austria, 1996) industrial synthesis → Farlow 2001 AD trial → FDA 2001 (Razadyne, Janssen / Shire; previously Reminyl). ANTIDOTE LINEAGE: Atropine 1831 → BAL Peters/Stocken/Thompson Oxford 1940s → 2-PAM Wilson/Ginsburg US Army 1955-1956 → Obidoxime 1964 (Erdmann/Engelhard) → TMB-4 Ludewig/Lohs 1950s → HI-6 Hagedorn/Oldiges/Schoene 1960s-70s → Carb-oxime Institute of Toxicology St. Petersburg late 1990s-2000s → Pelixim (auto-injector). CHOLINERGIC HYPOTHESIS OF AD: Davies & Maloney 1976 Lancet → Bartus, Dean, Beer & Lippa 1982 Science 217:408-417 → Francis, Palmer, Snape & Wilcock 1999 JNNP 66:137-147 → Котов А.С. et al. 2015 Медицинский совет (Russian-language review of the hypothesis)..
- COI note
- The compound-level COI is structurally lower than for bioregulators or actoprotectors — galantamine's Western development was carried out by independent commercial actors (Janssen/Shire/Sanochemia) and the AChE inhibitor class is now generic. The state-programme COI (Soviet nerve-agent disclosure) is a different kind of issue — Mirzayanov's 1992 disclosure in Moscow News and 2008 memoir is the primary documentation; subsequent academic syntheses (Kloske & Witkiewicz 2019 Chemosphere; Opravil, Pejchal, Finger et al. 2023 Arch Toxicol) constitute independent secondary review. The Mashkovsky attribution correction (this dossier, not 'Margolin 1951') is the honest framing for the 1951 galantamine discovery.
3 · Mechanism — claim by claim
01
IRREVERSIBLE AChE INHIBITORS (tabun 1936, sarin 1938, soman 1944, VX 1952, A-series 1970s-1993) phosphorylate the active-site serine, producing an enzyme adduct that ages (dealkylation of the phosphyl group) over minutes-to-hours, after which oxime rescue becomes impossible. Soviet programme: GosNIIOKhT Foliant / A-series 1971-1993, disclosed by Mirzayanov 1992; OPCW added A-series to Schedule 1 in November 2019 after Salisbury (2018) and Navalny (2020).
Toxicity 5-8× VX claimed in memoirs; not independently peer-reviewed. Russian state media disputes Mirzayanov's structural claims; Leonid Rink (2018) confirmed structures are correct. Open survey: Opravil, Pejchal, Finger et al. 2023 Arch Toxicol — explicitly states the term 'Novichok' was never used inside the programme; it appears only in Western reporting after 1992.
02
OXIME AChE REACTIVATORS restore enzymatic function by nucleophilic attack on the P-O bond at the esteratic site. Soviet doctrine favoured bis-pyridinium dioximes (dipyroxime / TMB-4 was the principal Soviet nerve-agent reactivator 1960s-1991). After Latvian TMB-4 production ceased, Institute of Toxicology St. Petersburg developed carb-oxime (partial BBB penetration, reactivates 15-30% of brain AChE in rats; aqueous stability ≥3 yr at ≤25 °C — major advantage over HI-6). Pelixim is the modern Russian auto-injector combining carboxime with anticholinergic.
Pralidoxime / 2-PAM (1955-1956 US Army) is the Western equivalent; registered in Russia as Pelixim in combination with anticholinergic. Obidoxime (1964 Erdmann/Engelhard) is broader-spectrum against OP pesticides but Petrov 2004 notes it is 'малоэффективен в отношении ФОВ' (largely ineffective against classical nerve agents). HI-6 (Hagedorn 1960s-70s, Bundeswehr) is the most-tested Western H-oxime; Russia evaluated but did not adopt it.
03
CARBAMATE REVERSIBLE AChE INHIBITORS transiently occupy the active site, protecting it from irreversible OP phosphorylation. Pyridostigmine is the Western prophylactic. Soviet equivalents: aminostigmine (Sofronov/Prozorovskii 1991, Institute of Toxicology; approved in Russia for central anticholinergic syndrome, studied as FOV prophylactic). Physostigmine (Fraser 1862, Jobst & Hesse 1864, Julian & Pikl total synthesis 1935) crosses BBB; the foundational experimental tool for chemical neurotransmission — Loewi 1926 used physostigmine to isolate acetylcholine (1936 Nobel). Galantamine is both a prophylactic-candidate AND an Alzheimer therapeutic.
Galantamine is unique among marketed anti-dementia drugs: dual mode — reversible competitive AChE inhibition + positive allosteric modulator of presynaptic α7 and α4β2 nicotinic receptors (nAChR PAM). Russian Institute of Toxicology noted the limitation that natural galantamine is harvested from Caucasian snowdrops that don't grow in sufficient quantity in Russia, which is why they developed synthetic aminostigmine instead.
04
MUSCARINIC ANTAGONISTS (atropine 1831) block muscarinic ACh receptors but do not reactivate AChE and do not block nicotinic effects (skeletal-muscle fasciculations, paralysis). Pentiphine (Kosmachev/Belyaev/Sofronov 1998-2003, Institute of Toxicology) is a centrally-acting M1 + nicotinic cholinoblocker, superior to atropine at blocking FOV-induced seizures — drove the modern multi-component Russian antidote kit (П-10М).
Standard anticholinergic base of self/buddy-aid kits; Soviet soldier issued 3 × 2 mg auto-injectors. Combined with reactivator and prophylactic in three-tier system: тарен / афин / будаксим (1960s-70s); П-10М / пеликсим (today).
05
ALZHEIMER'S THERAPEUTICS exploit the cholinergic hypothesis of AD (Davies & Maloney 1976 Lancet; Bartus, Dean, Beer & Lippa 1982 Science 217:408-417) — the cholinergic deficit in basal forebrain nuclei (nucleus basalis of Meynert) underlies cognitive decline. Tacrine (Summers 1981; FDA 1993, withdrawn 2013) was the first AChE inhibitor for AD. Donepezil / Aricept (Eisai E2020, FDA November 1996) — non-covalent reversible. Rivastigmine / Exelon (Weinstock-Rosin, FDA 2000) — carbamate 'pseudo-irreversible', binds both AChE and BuChE with preference for BuChE; first derived from rational pharmacophore design on the physostigmine scaffold. Galantamine (FDA 2001) — see this dossier. Huperzine A (Chinese, 1986) — dual AChE/NMDA mechanism; studied in Russia as FOV prophylactic.
Russian ЖНВЛП list includes galantamine, rivastigmine, donepezil. Котов А.С. et al. 2015 Медицинский совет (CyberLeninka) reviews the cholinergic hypothesis in Russian; Белоусов Ю.Б. et al. 2009 covers clinical-economic aspects in Russia; Трофимова Е.О. et al. 2019 covers the Russian dementia drug market.
4 · Roster — verified compounds
| Name | Subclass | Institution / status | Year | Note | Voynich |
|---|---|---|---|---|---|
| Tabun | Irreversible AChE inhibitor (OP nerve agent) | IG Farben — Schrader G | 1936 | CW (Nazi stockpile; weaponised by USSR post-1945) | LOW |
| Sarin | Irreversible AChE inhibitor (OP nerve agent) | IG Farben — Schrader G | 1938 | CW (Tokyo subway 1995; Syria 2013, 2017) | LOW |
| Soman | Irreversible AChE inhibitor (OP nerve agent, fast aging) | Kaiser Wilhelm Institute — Kuhn R | 1944 | CW; aging makes oxime rescue essentially impossible | LOW |
| VX / R-33 / VR / RVX | Irreversible AChE inhibitor (OP nerve agent, persistent) | ICI Porton Down — Ghosh R | 1952 | CW; assassination of Kim Jong-nam 2017 | LOW |
| A-230 / A-232 / A-234 / A-242 | Irreversible AChE inhibitor (A-series, Foliant) | GosNIIOKhT — Mirzayanov VS / Fedorov L | 1970s-1993 | CW (disputed; OPCW Schedule 1 November 2019 after Salisbury 2018 and Navalny 2020) | partial — Mirzayanov 1992 disclosure + 2008 memoir; Russian state media disputes structures |
| Atropine | Muscarinic antagonist | Multiple — Mein 1831 | 1831 | Standard anticholinergic base of self/buddy-aid kits | LOW |
| Pralidoxime (2-PAM) | Pyridinium mono-oxime reactivator | US Army Edgewood — Wilson IB / Ginsburg S | 1955-1956 | Western military auto-injector; in Russia as Pelixim combination | LOW |
| Obidoxime (Toxogonin) | Bis-pyridinium 4,4'-dioxime reactivator | Erdmann / Engelhard | 1964 | OP-pesticide poisoning; largely ineffective against classical nerve agents per Petrov 2004 | LOW |
| Dipyroxime (TMB-4) | Bis-pyridinium 4,4'-dioxime reactivator | Ludewig / Lohs; adopted by Soviet bloc | 1950s | Principal Soviet nerve-agent reactivator 1960s-1991 (Latvian SSR production; ceased after USSR breakup) | LOW |
| Isonitrosine | Mono-oxime reactivator | Soviet-era | Soviet era | First-generation oxime, used with atropine for OP poisoning | LOW |
| HI-6 / asoxime | Bis-pyridinium mono-oxime (H-oxime) | Hagedorn / Oldiges / Schoene (Bundeswehr) | 1960s-70s | Western standard reactivator; Russia evaluated but did not adopt | LOW |
| Carb-oxime | Bis-quaternary mono-oxime reactivator (partial BBB) | Institute of Toxicology St. Petersburg — Petrov / Sofronov | late 1990s-2000s | Russian military auto-injector; replaces dipyroxime/TMB-4 post-1991 | LOW |
| Aminostigmine | Tertiary-amine carbamate reversible AChEI | Institute of Toxicology St. Petersburg — Sofronov / Prozorovskii | 1991-1992 | Approved Russia for central anticholinergic syndrome; studied as FOV prophylactic | LOW |
| Pentiphine | M1 + nicotinic cholinoblocker | Institute of Toxicology — Kosmachev / Belyaev / Sofronov | 1998-2003 | Component of modern Russian multi-drug kit (П-10М) | LOW |
| Physostigmine (Eserine) | Carbamate reversible AChEI (BBB-permeable) | Calabar bean (Physostigma venenosum) — Fraser 1862; Jobst & Hesse 1864; Julian & Pikl total synthesis 1935 | 1863/1864 | Medicine + experimental tool (Loewi 1926 → 1936 Nobel) | LOW |
| Galantamine (Nivalin, Reminyl, Razadyne) | Phenanthridine alkaloid; reversible AChEI + nAChR PAM | ВНИХФИ Moscow — Mashkovsky MD + Kruglikova-Lvova RP (1951); Pharmachim Sofia — Paskov D (1956-1959) | 1951 (AChE pharmacology); 1958 (Nivalin drug) | Approved FDA 2001 (Razadyne) for mild-to-moderate Alzheimer's; on Russian ЖНВЛП list; studied for FOV prophylaxis | LOW |
| Tacrine (THA, Cognex) | Acridine reversible AChEI | ICI — Albert / Gledhill (1945); Summers WK (Loma Linda VA, 1981 AD indication) | 1945 (synth); 1981 (AD indication); FDA 1993 | First AChE inhibitor for AD; withdrawn 2013 (hepatotoxicity) | LOW |
| Rivastigmine (Exelon) | Carbamate 'pseudo-irreversible' AChEI / BuChEI | Hebrew Univ. Jerusalem — Weinstock-Rosin M | 1990s; FDA 2000 | First AChE inhibitor derived from rational pharmacophore design on physostigmine scaffold; binds both AChE and BuChE | LOW |
| Donepezil (Aricept) | Benzylpiperidine non-covalent reversible AChEI | Eisai (E2020) | 1980s-90s; FDA November 1996 | Once-daily dosing; long CNS half-life | LOW |
| Huperzine A | Lycopodium alkaloid; reversible AChEI + NMDA antagonist | Chinese — Liu / Bai 1986 | 1986 | AD candidate; studied in Russia as dual AChE/NMDA + FOV-prophylactic | LOW |
5 · The Galantamine Attribution Correction — important
Wrong attribution: Margolin 1951
Correct attribution: M.D. Mashkovsky and R.P. Kruglikova-Lvova (ВНИХФИ, Moscow), Фармакология и токсикология 14:27-30 (1951) 'О фармакологии нового алкалоида галантамина'
Second attribution (drug development): Dimitar Paskov (Bulgaria, 1956-1959) — developed galantamine as a marketed drug under the brand name Nivalin (Pharmachim, Sofia, 1958). The Russian / Bulgarian drug history is joint, but the AChE pharmacology discovery is Mashkovsky & Kruglikova-Lvova 1951.
Western development: Sanochemia (Austria, 1996) — first synthetic industrial route; Farlow et al. 2001 — pivotal AD trial; FDA approval 2001 (Razadyne, Janssen/Shire); ATC N06DA04; on Russian ЖНВЛП list
Supporting evidence
- Mashkovsky 110th-birthday tribute (Konorev 2018, CyberLeninka)
- Heinrich & Lee 2004 J Ethnopharmacol review of Galantthus woronowii traditional use → modern pharmacology
- Russian Wikipedia Галантамин citing both the 1951 paper and the Mashkovsky 1955 follow-up
- Bokov DO et al. 2015 — Сеченовский вестник — on G. woronowii as medicinal plant raw material
8 · The lineage — visualized
Calabar bean (Efik, Nigeria, ~17th c.) → Fraser 1862 eserine → Jobst & Hesse 1864 physostigmine → Loewi 1926 (uses physostigmine, isolates acetylcholine, 1936 Nobel) → acetylcholine / cholinergic neurotransmission established. ↓ Tabun (Schrader 1936) → Sarin (1938) → Soman (Kuhn 1944) → VX (Ghosh 1952) → Foliant / A-series (GosNIIOKhT 1971-1993; Mirzayanov disclosure 1992). PARALLEL: Caucasian snowdrop (Galanthus woronowii) → Mashkovsky & Kruglikova-Lvova 1951 → Mashkovsky 1955 → Paskov Bulgaria 1956-1959 → Nivalin Pharmachim 1958 → Bandman & Anriiyanov 1982 → Heinrich & Lee 2004 → Sanochemia 1996 (synthetic) → Farlow 2001 AD trial → FDA 2001 Razadyne. ANTIDOTE PARALLEL: Atropine (1831) → Pralidoxime 2-PAM (1956) → Obidoxime (1964) → Dipyroxime TMB-4 (1950s, Soviet) → HI-6 (Hagedorn 1960s-70s) → Carb-oxime (Институт токсикологии СПб 2000s, Russian) → Pelixim (auto-injector) → Pentiphine (1998-2003) → Aminostigmine (1991). CHOLINERGIC HYPOTHESIS OF AD (Davies & Maloney 1976; Bartus et al. 1982; Francis et al. 1999) → Tacrine (FDA 1993, withdrawn 2013) → Donepezil (FDA 1996) → Rivastigmine (FDA 2000, physostigmine-scaffold carbamate) → Galantamine (FDA 2001) → Huperzine A (Chinese; FOV-prophylactic).
9 · Anchors
| Identifier | Claim |
|---|---|
| CyberLeninka: antidote-fos | Petrov AN / Sofronov GA / Nechiporenko SP / Somin IN 2004 Ros. khim. zh. 48(2):110-116 — Antidotes of organophosphorus poisonous substances; canonical Russian open review |
| CyberLeninka: mihail-davydovich-mashkovskiy | Konorev MR et al. 2018 — Mikhail Davydovich Mashkovsky: contribution to modern pharmacology (110th birthday tribute) |
| CyberLeninka: bolezn-altsgeymera | Котов А.С. et al. 2015 Медицинский совет — Alzheimer's disease: from theory to practice; cholinergic hypothesis review |
| CyberLeninka: otsenka-reaktivatora-holinesterazy-karboksima | Prozorovskii VB 2008 — Carb-oxime prophylaxis evaluation |
| CyberLeninka: reaktivatory-holinesterazy | Gladkov VD / Nazarov VB 2014 экстремальная биомедицина — AChE reactivators in neurotoxic exposures |
| CyberLeninka: kliniko-ekonomicheskie-aspekty-terapii | Белоусов Ю.Б. et al. 2009 — Clinical-economic aspects of AD therapy in Russia |
| CyberLeninka: analiz-rynka-preparatov-dlya-lecheniya-dementsii | Трофимова Е.О. et al. 2019 — Russian dementia drug market analysis |
| CyberLeninka: distantnoe-deystvie | Prozorovskii VB 2004 — Distant action in the pathogenesis of organophosphate poisoning; historical review of Soviet OP-inhibitor pharmacology |
| CyberLeninka: rol-holinergicheskogo-defitsita | Дзяк Л.А. et al. 2019 — Role of cholinergic deficit in psychoneurological disease pathogenesis |
| disserCat: galantamin | Danilov MS 2019 — Galantamine in prophylaxis and treatment of central anticholinergic syndrome after general anaesthesia; confirms Russian clinical use |
| Mirzayanov 2008 State Secrets (Outskirts Press) | Vil Mirzayanov memoir; primary source for A-230, A-232, A-234, A-242, Novichok-5, Novichok-7 binary formulations |
| Chai 2018 Toxicol Commun 2:45-48 | Chai / Hayes / Erickson / Boyer — Novichok agents: historical, current, toxicological perspective |
| Kloske & Witkiewicz 2019 Chemosphere 221:672-682 | Novichoks — the A group of organophosphorus chemical warfare agents; independent secondary review |
| Opravil 2023 Arch Toxicol 97:2587-2607 | A-agents, misleadingly known as 'Novichoks': narrative review; explicitly states 'Novichok' was never used inside the programme |
| Mashkovsky & Kruglikova-Lvova 1951 Фармакология и токсикология 14:27-30 | On the pharmacology of a new alkaloid galantamine — primary discovery paper; the correct attribution (NOT 'Margolin 1951') |
| Mashkovsky 1955 Фармакология и токсикология | Second anticholinesterase paper; follow-up pharmacology |
| Heinrich & Lee 2004 J Ethnopharmacol | Review of traditional use → modern pharmacology of Galanthus woronowii; canonical Western review citing the 1951 Mashkovsky paper |
| Bartus, Dean, Beer & Lippa 1982 Science 217:408-417 | The cholinergic hypothesis of geriatric memory dysfunction; foundational Alzheimer's paper |
| Davies & Maloney 1976 Lancet | Cholinergic deficit in Alzheimer's disease — original Lancet paper |
10 · Corroboration
- Verified
- 2026-08-27
- Method
- Cross-referenced against CyberLeninka, PubMed E-utilities, and the canonical Russian organophosphate-antidote review (Petrov 2004). The galantamine attribution is corrected from the secondary literature.
11 · Open questions
- Verify that all six Russian antidotes (atropine / 2-PAM / dipyroxime / isonitrosine / carb-oxime / aminostigmine / pentiphine) appear in the modern Russian military auto-injector (П-10М / пеликсим) — the multi-drug combination is closed protocol
- Map the A-series agents claimed in Mirzayanov 2008 (A-230, A-232, A-234, A-242, Novichok-5, Novichok-7) against any independent mass-spectral confirmation from the Salisbury 2018 or Navalny 2020 OPCW-designated laboratories
- Cross-reference the Mashkovsky & Kruglikova-Lvova 1951 paper against the ВНИХФИ Moscow archive — the primary paper is cited universally, but the lab-notebook record of the extraction (from Galanthus woronowii bulbs) is the original-source question
- Quantify the Bulgarian Pharmachim Nivalin production 1958-onwards — the commercial track of the Soviet discovery
- Identify whether huperzine A is approved in Russia (the dual AChE/NMDA mechanism makes it the most pharmacologically interesting 'minor' AChE inhibitor, but Russian clinical use is unclear)
- Map the aminostigmine clinical evidence — Sofronov 1991 paper establishes chemistry; clinical files for FOV prophylaxis are not in the open record